Health Outcomes of Parents With Cystic Fibrosis
- Conditions
- Cystic FibrosisParenthood Status
- Interventions
- Other: Parental Status
- Registration Number
- NCT05829694
- Lead Sponsor
- University of Pittsburgh
- Brief Summary
This project will determine the health impact of parenthood on people with cystic fibrosis (CF). The study team will use retrospective data to provide relatively immediate evidence on parenthood's effect on pulmonary health.
- Detailed Description
This co-funded study sponsored by the National Institutes of Health and the CF Foundation (CFF) will seek to determine the health impact of parenthood on people with CF in the era of CF transmembrane conductance regulator (CFTR) modulators. To provide relatively immediate evidence on parenthood's effect on pulmonary health and the influence of the introduction and use of all available CFTR modulators, in Aim 1 the study team will assess changes in pre- vs. intra-parenthood percent predicted forced expiratory volume in 1 second (ppFEV1) in a retrospective longitudinal cohort study linking CFF patient registry (CFFPR) data with cross-sectional surveys collected from 249 new parents attending participating United States CF centers between 2012-2022. The study team will identify predictors and timing of lung function loss using 747 non-parents from participating centers as a comparison group and examine the impact of CFTR modulators on parental health.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 996
- Confirmed CF diagnosis with sweat or genotype analysis
- Participant in the CFFPR
- Became a first-time parent between the years 2012-2022 (exposure arm only)
- Lung transplant prior to becoming a first-time parent (exposure arm) or prior to study period (control)
- Does not speak/read English or Spanish
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Parents Parental Status Individuals diagnosed with cystic fibrosis who became a first-time parent between January 1, 2012 and December 31, 2022.
- Primary Outcome Measures
Name Time Method FEV1 2012-2022 Rate of decline of ppFEV1 as reported in the CFFPR
- Secondary Outcome Measures
Name Time Method BMI 2012-2022 BMI as reported in the CFFPR
Rate of pulmonary exacerbations 2012-2022 Rate of pulmonary exacerbations as reported in the CFFPR
Clinic visit attendance 2012-2022 Clinic visit attendance as reported in the CFFPR
Medication Use 2012-2022 Medication use as reported in the CFFPR
CFRD Control 2012-2022 HbgA1c as reported in the CFFPR
Rate of hospitalizations 2012-2022 Rate of hospitalizations as reported in the CFFPR
Microbiologic profile 2012-2022 Presence of specific types of bacteria, mycobacteria, fungus in cultures as reported in the CFFPR
Trial Locations
- Locations (8)
National Jewish Health
๐บ๐ธDenver, Colorado, United States
Johns Hopkins University
๐บ๐ธBaltimore, Maryland, United States
Massachusetts General Hospital
๐บ๐ธBoston, Massachusetts, United States
University of Minnesota
๐บ๐ธMinneapolis, Minnesota, United States
University of North Carolina
๐บ๐ธChapel Hill, North Carolina, United States
UPMC
๐บ๐ธPittsburgh, Pennsylvania, United States
University of Texas-Southwestern
๐บ๐ธDallas, Texas, United States
University of Washington
๐บ๐ธSeattle, Washington, United States